Identifying an optimum treatment strategy for patients with advanced non-small cell lung cancer

Critical Reviews in Oncology/Hematology

Volumn 67, Issue 1, 2008, Pages 16-26

  Grossi, Francesco ^a   Gridelli, Cesare ^b   Aita, Marianna ^c   De Marinis, Filippo ^d  

^a UNIVERSITY OF GENOA   (Italy)

^b S G MOSCATI HOSPITAL   (Italy)

^c UNIVERSITY HOSPITAL OF UDINE   (Italy)

^d SAN CAMILLO FORLANINI HOSPITAL   (Italy)

Author keywords

Advanced non small cell lung cancer; Biological drugs; First line chemotherapy; Second line therapy; Third line therapy; Treatment strategy

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; ERLOTINIB; GEFITINIB; GEMCITABINE; N (3,3 DIMETHYL 6 INDOLINYL) 2 (4 PYRIDINYLMETHYLAMINO)NICOTINAMIDE; NAVELBINE; PACLITAXEL; PEMETREXED; PLACEBO; PLATINUM DERIVATIVE; SORAFENIB; SUNITINIB;

ADVANCED CANCER; ANEMIA; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE CLASSIFICATION; DOSAGE SCHEDULE COMPARISON; HISTOPATHOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; REVIEW; THROMBOCYTOPENIA; TREATMENT PLANNING;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; HUMANS; LUNG NEOPLASMS; NEOPLASM METASTASIS;

EID: 44949185573     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2007.12.002     Document Type: Review

References (64)

1. Kelly K., Crowley J., Bunn P., et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 19 (2001) 3210-3218
2. Schiller J.H., Harrington D., Belani C.P., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346 (2002) 92-98
3. Scagliotti G.V., De Marinis F., Rinaldi M., et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small cell lung cancer. J Clin Oncol 20 (2002) 4285-4291
4. Smit E.F., van Meerbeeck J.P., Lianes P., et al. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group-EORTC 08975. J Clin Oncol 21 (2003) 3909-3917
5. Fossella F., Pereira J.R., von Pawel J., et al. Randomized, multinational, Phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small cell lung cancer: the TAX 326 Study Group. J Clin Oncol 21 (2003) 3016-3024
6. Georgoulias V., Papadakis E., Alexopoulos A., et al. Platinum-based and non-platinum-based chemotherapy in advanced non-small cell lung cancer: a randomized multicentre trial. Lancet 357 (2001) 1478-1484
7. Georgoulias V., Ardavanis A., Tsiafaki X., et al. Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 23 (2005) 2937-2945
8. Pujol J.L., Breton J.L., Gervais R., et al. Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin. Ann Oncol 16 (2005) 602-610
9. Gridelli C., Gallo C., Shepherd F., et al. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non small cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trial Group. J Clin Oncol 21 (2003) 3025-3034
10. Pfister D.G., Johnson D.H., Azzoli C.G., et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 22 (2004) 330-353
11. Socinski M.A. Cytotoxic chemotherapy in advanced non-small cell lung cancer: a review of standard treatment paradigms. Clin Cancer Res 10 (2004) s4210s-s4214s
12. Le Chevalier T., Scagliotti G., Natale R., et al. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer 47 (2005) 69-80
13. Douillard J.Y., Laporte S., Fossella F., et al. Comparison of docetaxel- and vinca alkaloid-based chemotherapy in the first-line treatment of advanced non-small cell lung cancer: a meta-analysis of seven randomized clinical trials. J Thorac Oncol 2 (2007) 939-946
14. Grossi F., Belvedere O., Defferrari C., Vinante O., and Pappagallo G. Impact of third generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer (NSCLC): a meta-analytical approach. Ann Oncol 17 S11 (2006) xi25
15. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in NSCLC: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311 (1995) 899-909
16. Ardizzoni A., Boni L., Tiseo M., et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 99 (2007) 847-857
17. Hotta K., Matsuo K., Ueoka H., Kiura K., Tabata M., and Tanimoto M. Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 22 (2004) 3852-3859
18. Zojwalla N.J., Raftopoulos H., and Gralla R.J. Are cisplatin and carboplatin equivalent in the treatment of non-small cell lung carcinoma (NSCLC)? Results of a comprehensive review of randomized studies in over 2500 patients. J Clin Oncol 22 S14 (2004) 7068
19. Pujol J.L., Barlesi F., and Daures J.P. Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials. Lung Cancer 51 (2006) 335-345
20. Lord R.V., Brabender J., Gandara D., et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 8 (2002) 2286-2291
21. Ceppi P., Volante M., Novello S., et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol 17 (2006) 1818-1825
22. Cobo M., Isla D., Massuti B., et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 25 (2007) 2747-2754
23. Simon G., Sharma A., Li X., et al. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. J Clin Oncol 25 (2007) 2741-2746
24. Rosell R., Danenberg K.D., Alberola V., et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 10 (2004) 1318-1325
25. Delbaldo C., Michiels S., Syz N., Soria J.C., Le Chevalier T., and Pignon J.P. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA 292 (2004) 470-484
26. Paccagnella A., Oniga F., Bearz A., et al. Adding gemcitabine to paclitaxel/carboplatin combination increases survival in advanced non-small-cell lung cancer: results of a phase II-III study. J Clin Oncol 24 (2006) 681-687
27. Grossi F., Aita M., Follador A., et al. Sequential, alternating, and maintenance/consolidation chemotherapy in advanced non-small cell lung cancer: a review of the literature. Oncologist 12 (2007) 451-464
28. Gridelli C. Does palliative chemotherapy beyond three courses benefit patients with non small cell lung cancer?. Nat Clin Pract Oncol 4 (2007) 274-275
29. Smith I.E., O'Brien M.E., Talbot D.C., et al. Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol 19 (2001) 1336-1343
30. Socinski M.A., Schell M.J., Peterman A., et al. A phase III trial comparing a defined duration of therapy vs continuous therapy followed by second-line therapy in advanced stage IIIB/IV non-small cell lung cancer. J Clin Oncol 20 (2002) 1335-1343
31. Fidias P., Dakhil S.R., Lyss A.P., et al. Phase III study of immediate versus delayed docetaxel after induction therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer: updated report with survival. J Clin Oncol 25 (2007) LBA7516
32. Herbst R.S., Giaccone G., Schiller J.H., et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 22 (2004) 785-794
33. Gatzemeier U., Pluzanska A., Szczesna A., et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 25 (2007) 1545-1552
34. Herbst R.S., Prager D., Hermann R., et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23 (2005) 5892-5899
35. Giaccone G., Herbst R.S., Manegold C., et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 22 (2004) 777-784
36. Johnson D.H., Fehrenbacher L., Novotny W.F., et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic nonsmall-cell lung cancer. J Clin Oncol 22 (2004) 2184-2191
37. Sandler A., Gray R., Perry M.C., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355 (2006) 2542-2550
38. Manegold C., von Pawel J., Zatloukal P., et al. Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naïve patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704. J Clin Oncol 25 S18 (2007) LBA7514
39. http://www.emea.europa.eu/pdfs/human/press/pr/32370307en.pdf.
40. Scagliotti G., Purvish P., von Pawel J., et al. Phase III study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). J Thoracic Oncol 2 Suppl. 4 (2007) PRS-03
41. Ramalingam S.S., Dahlberg S.E., and Langer C.J. et al. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol 26 (2008) 60-65
42. Gridelli C., Maione P., Del Gaizo F., et al. Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer. Oncologist 12 (2007) 191-200
43. http://clinicaltrials.gov/show/NCT00300885.
44. http://clinicaltrials.gov/show/NCT00449033.
45. http://clinicaltrials.gov/show/NCT00460317.
46. http://clinicaltrials.gov/show/NCT00434226.
47. Shepherd F.A., Dancey J., Ramlau R., et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18 (2000) 2095-2103
48. Fossella F.V., DeVore R., Kerr R.N., et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 18 (2000) 2354-2362
49. Hanna N., Shepherd F.A., Fossella F.V., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22 (2004) 1589-1597
50. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353 (2005) 123-132
51. Massarelli E., Andre F., Liu D.D., et al. A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. Lung Cancer 39 (2003) 55-61
52. Toschi L., and Cappuzzo F. Understanding the new genetics of responsiveness to epidermal growth factor receptor tyrosine kinase inhibitors. Oncologist 12 (2007) 211-220
53. Bhalla S., Thatcher N., Reck M., et al. Does reporting expected duration and severity of adverse events provide clinically relevant information when selecting a chemotherapy regimen? An example using pemetrexed and docetaxel. Lung Cancer 49 S1 (2005) 85-86
54. Pujol J.L., Paul S., Chouaki N., et al. Survival without common toxicity criteria grade 3/4 toxicity for pemetrexed compared with docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): a risk-benefit analysis. J Thorac Oncol 2 (2007) 397-401
55. De Marinis F., Pereira J.R., Fossella F., et al. Lung Cancer Symptom Scale outcomes in relation to standard efficacy measures: an analysis of the phase III study of pemetrexed versus docetaxel in advanced non-small cell lung cancer. J Thorac Oncol 3 (2008) 30-36
56. Gervais R., Ducolone A., Breton J.L., et al. Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC). Ann Oncol 16 (2005) 90-96
57. Camps C., Massuti B., Jimenez A., et al. Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial. Ann Oncol 17 (2005) 467-472
58. Schuette W., Nagel S., Blankenburg T., et al. Phase III of second-line chemotherapy for advanced non-small cell lung cancer (NSCLC) with weekly compared with 3-weekly docetaxel. J Clin Oncol 23 (2005) 8389-8395
59. Gridelli C., Gallo C., Di Maio M., et al. A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study. Br J Cancer 91 (2004) 1996-2004
60. Bria E., Cuppone F., Ciccarese M., et al. Weekly docetaxel as second line chemotherapy for advanced non-small cell lung cancer meta-analysis of randomized trials. Cancer Treat Rev 32 (2006) 583-587
61. Di Maio M., Perrone F., Chiodini P., et al. Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 25 (2007) 1377-1382
62. http://clinicaltrials.gov/show/NCT00404924.
63. http://clinicaltrials.gov/show/NCT00364351.
64. http://clinicaltrials.gov/show/NCT00457392.